CN102872141B - Application of Houttuynoid E in drug for treating liver cancer - Google Patents
Application of Houttuynoid E in drug for treating liver cancer Download PDFInfo
- Publication number
- CN102872141B CN102872141B CN201210419604.0A CN201210419604A CN102872141B CN 102872141 B CN102872141 B CN 102872141B CN 201210419604 A CN201210419604 A CN 201210419604A CN 102872141 B CN102872141 B CN 102872141B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- liver cancer
- drug
- preparing
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of Houttuynoid E in preparing a drug for treating liver cancer, belonging to the technical field of the new use of the drug. Houttuynoid E is found to have obvious inhibition effect on the growth of human liver cancer cell lines HepG2, MHCC-LM3, Bel-7402 and HuH-7 through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid E can be used for preparing the anti-liver cancer drug and has excellent prospects in development and application. The use of Houttuynoid E in preparing the drug for treating the liver cancer involved in the invention is disclosed for the first time; the framework type of Houttuynoid E is a brand new framework type; and Houttuynoid E has an unexpectedly high inhibition activity for the liver cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid E, relate in particular to the application of Houttuynoid E in preparing medicines resistant to liver cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid E the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), for the purposes in preparing Hepatoma therapy medicine the present invention relates to, belong to open first, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for hepatocarcinoma simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid E in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid E in preparing medicines resistant to liver cancer, and the structural formula of Houttuynoid E is as shown in formula I:
Formula I
The present invention finds by the evaluation of external MTT anti-tumor activity, and Houttuynoid E also has significant inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 2.29 ± 0.37 μ M, 1.49 ± 0.49 μ M, 3.44 ± 0.61 μ M and 2.22 ± 0.55 μ M.Therefore, Houttuynoid E can, for the preparation of medicines resistant to liver cancer, have good development prospect.
The present invention relates to the purposes of Houttuynoid E in preparing Hepatoma therapy medicine and belong to open first, because framework types belongs to brand-new framework types, and its inhibition for hepatoma carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for hepatocarcinoma simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid E to human hepatoma cell strain
1. method: the cell in growth logarithmic (log) phase: HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid E of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Houttuynoid E has significant inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7.This compound suppresses the IC of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7 growth
50value is respectively: 2.29 ± 0.37 μ M, 1.49 ± 0.49 μ M, 3.44 ± 0.61 μ M and 2.22 ± 0.55 μ M.
By above-described embodiment, shown, Houttuynoid E of the present invention has good inhibitory action to the growth of HepG2 cell lines, MHCC-LM3, Bel-7402 and HuH-7.Prove thus, Houttuynoid E of the present invention has resisting liver cancer activity, can be for the preparation of medicines resistant to liver cancer.
Claims (1)
- The application of 1.Houttuynoid E in preparing the medicine of Hepatoma therapy, described compound H outtuynoid E structure as formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419604.0A CN102872141B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in drug for treating liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419604.0A CN102872141B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in drug for treating liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872141A CN102872141A (en) | 2013-01-16 |
| CN102872141B true CN102872141B (en) | 2014-04-16 |
Family
ID=47473812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210419604.0A Expired - Fee Related CN102872141B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in drug for treating liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872141B (en) |
-
2012
- 2012-10-27 CN CN201210419604.0A patent/CN102872141B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872141A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861073B (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer | |
| CN102861089B (en) | Application of Houttuynoid B in medicine for treating liver cancer | |
| CN102872069B (en) | Application of Houttuynoid C to preparing drugs for treating liver cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872111B (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102861049B (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU KANGHENG CHEMICAL CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226500 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141202 Address after: 226500, Jiangsu, Rugao town (Rugao port area) 8 West Hong Kong Road (Fine Chemical Industry Park) Patentee after: Jiangsu Kangheng Chemical Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20191027 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |